Summary of Manufacturer Recommendations for Statin and Protease Inhibitor Drug Interactions as Described in Prescribing Information
| CYP3A4 Inhibitor | Simvastatin | Lovastatin | Atorvastatin | Pravastatin | Fluvastatin | Rosuvastatin |
|---|---|---|---|---|---|---|
| Atazanavir | Not recommended | Not recommended | Use with caution | Clinically significant DIs are not expected | Clinically significant DIs are not expected | N/A |
| Nelfinavir | Not recommended* | Not recommended | Use with caution | Considered safe | Considered safe | N/A |
| Ritonavir | Not recommended* | Not recommended | Use with caution | Considered safe | Considered safe | N/A |
| Indinavir | Not recommended | Not recommended | Use with caution | Considered safe | Considered safe | Considered safe |
| Saquinavir | Not recommended | Not recommended | Use with caution | Considered safe | Considered safe | Considered safe |
| Amprenavir | Not recommended | Not recommended | Use with caution | Considered safe | Considered safe | N/A |
| Fosamprenavir | Not recommended | Not recommended | Use with caution | Considered safe | Considered safe | Considered safe |
| Lopinavir/ritonavir | Not recommended | Not recommended | Use with caution* | Considered safe | Considered safe | N/A |
| Tipranavir | Not recommended | Not recommended | Use with caution | N/A | N/A | N/A |
* Rhabdomyolysis has been described.26,28–30
DI, drug interaction; N/A, interaction not reported.